Clinical, pharmacoepidemiological and pharmacoecomonic aspects of use of Akatinol (Memantine) in dementia
In the course of a naturalistic controlled 6-month-long prospective investigation, Memantine showed its superiority in the treatment of Alzheimer disease and vascular dementia, as compared to regular medication (vasoactive and nootropic drugs), in terms of behavior correction, control of psychopathological symptoms, relief of cognitive disorders, improvement of patients' functioning and relief of the burden of disease for formal and non-formal guardians.